Last reviewed · How we verify
dual-release hydrocortisone
Dual-release hydrocortisone delivers the corticosteroid in two phases to mimic the body's natural cortisol rhythm, providing anti-inflammatory and immunosuppressive effects.
Dual-release hydrocortisone delivers the corticosteroid in two phases to mimic the body's natural cortisol rhythm, providing anti-inflammatory and immunosuppressive effects. Used for Adrenal insufficiency (primary or secondary), Congenital adrenal hyperplasia.
At a glance
| Generic name | dual-release hydrocortisone |
|---|---|
| Also known as | Plenadren |
| Sponsor | University of Palermo |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
This formulation uses a modified-release technology to release hydrocortisone in two distinct phases—typically an immediate release component and a delayed release component—to replicate the diurnal pattern of endogenous cortisol secretion. By matching physiological cortisol levels throughout the day, dual-release hydrocortisone aims to improve efficacy while potentially reducing adverse effects associated with conventional immediate-release formulations.
Approved indications
- Adrenal insufficiency (primary or secondary)
- Congenital adrenal hyperplasia
Common side effects
- Hyperglycemia
- Hypertension
- Osteoporosis
- Insomnia
- Mood changes
Key clinical trials
- Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre (NA)
- Adjunctive Fludrocortisone in Septic Shock (PHASE2)
- Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease (PHASE2, PHASE3)
- Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment (PHASE4)
- Effect of Melatonin on Postoperative Pain After Simple Nephrectomy (EARLY_PHASE1)
- Hydrocortisone Plus Fludrocortisone in High-risk Patients Undergoing for Cardiac Surgery (PHASE3)
- Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia (PHASE3)
- Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insufficiency (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |